Ivax Diagnostics CEO and president retires

TriMed Staff | | Health Imaging | Artificial Intelligence
After 27 years in the position, Giorgio D'Urso is resigning as president and CEO of Ivax Diagnostics, as well as a member of the board of directors of Ivax, effective Jan. 10.

The Miami-based Ivax also said that Kevin D. Clark, its chief operating officer (COO) since September 2007, has been appointed acting CEO, effective from D'Urso's resignation. Clark will remain in that position until the time the company names D'Urso's permanent successor.

In addition to serving as acting CEO, Clark will continue to serve as COO of Ivax and as COO of ImmunoVision, Ivax’s wholly-owned subsidiary which develops, manufactures and markets autoimmune reagents and research products for use by research laboratories and commercial diagnostic manufacturers.

TriMed Staff

Related Content

Deep learning-based reconstructions nearly halve acquisition time of spinal MRIs
Experts highlight 'significant concerns' with fluctuating accuracy of popular large language models
FDA clears AI screening tool for cardiac amyloidosis
Are providers too trusting of AI's advice?
Pairing an alert system with CAD software halves time-to-treatment for pneumothorax
Deep learning reconstruction cuts radiation and contrast dose by half in aortic CTA exams

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.